BIOLASE (BIOL) Competitors $0.01 +0.00 (+2.50%) As of 04/29/2025 Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock BIOL vs. NVIVQ, DYNT, BJDX, AFIB, CUTR, LGMK, SONX, GMVDF, SDCCQ, and VRAYQShould you be buying BIOLASE stock or one of its competitors? The main competitors of BIOLASE include Invivo Therapeutics (NVIVQ), Dynatronics (DYNT), Bluejay Diagnostics (BJDX), Acutus Medical (AFIB), Cutera (CUTR), LogicMark (LGMK), Sonendo (SONX), G Medical Innovations (GMVDF), SmileDirectClub (SDCCQ), and ViewRay (VRAYQ). These companies are all part of the "medical equipment" industry. BIOLASE vs. Invivo Therapeutics Dynatronics Bluejay Diagnostics Acutus Medical Cutera LogicMark Sonendo G Medical Innovations SmileDirectClub ViewRay Invivo Therapeutics (NASDAQ:NVIVQ) and BIOLASE (NASDAQ:BIOL) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, media sentiment, community ranking, earnings, institutional ownership, profitability, risk, dividends and analyst recommendations. Do analysts rate NVIVQ or BIOL? BIOLASE has a consensus price target of $1.20, indicating a potential upside of 9,656.10%. Given BIOLASE's stronger consensus rating and higher possible upside, analysts clearly believe BIOLASE is more favorable than Invivo Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Invivo Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00BIOLASE 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Which has preferable valuation and earnings, NVIVQ or BIOL? Invivo Therapeutics has higher earnings, but lower revenue than BIOLASE. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInvivo TherapeuticsN/AN/A-$10.49MN/AN/ABIOLASE$48.83M0.01-$20.63M-$14.940.00 Does the media refer more to NVIVQ or BIOL? In the previous week, BIOLASE had 1 more articles in the media than Invivo Therapeutics. MarketBeat recorded 1 mentions for BIOLASE and 0 mentions for Invivo Therapeutics. Invivo Therapeutics' average media sentiment score of 0.00 equaled BIOLASE'saverage media sentiment score. Company Overall Sentiment Invivo Therapeutics Neutral BIOLASE Neutral Is NVIVQ or BIOL more profitable? Invivo Therapeutics has a net margin of 0.00% compared to BIOLASE's net margin of -41.65%. Invivo Therapeutics' return on equity of 0.00% beat BIOLASE's return on equity.Company Net Margins Return on Equity Return on Assets Invivo TherapeuticsN/A N/A N/A BIOLASE -41.65%-1,782.73%-55.31% Which has more volatility and risk, NVIVQ or BIOL? Invivo Therapeutics has a beta of 0.4, suggesting that its stock price is 60% less volatile than the S&P 500. Comparatively, BIOLASE has a beta of 0.67, suggesting that its stock price is 33% less volatile than the S&P 500. Do insiders & institutionals have more ownership in NVIVQ or BIOL? 12.3% of Invivo Therapeutics shares are owned by institutional investors. Comparatively, 8.8% of BIOLASE shares are owned by institutional investors. 2.5% of Invivo Therapeutics shares are owned by insiders. Comparatively, 0.3% of BIOLASE shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the MarketBeat Community believe in NVIVQ or BIOL? BIOLASE received 292 more outperform votes than Invivo Therapeutics when rated by MarketBeat users. CompanyUnderperformOutperformInvivo TherapeuticsN/AN/ABIOLASEOutperform Votes29251.23% Underperform Votes27848.77% SummaryBIOLASE beats Invivo Therapeutics on 7 of the 13 factors compared between the two stocks. Get BIOLASE News Delivered to You Automatically Sign up to receive the latest news and ratings for BIOL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BIOL vs. The Competition Export to ExcelMetricBIOLASEDental equipment & supplies IndustryMedical SectorNASDAQ ExchangeMarket Cap$411,000.00$4.03B$5.57B$7.83BDividend YieldN/A2.47%5.11%4.22%P/E Ratio0.0053.1522.4218.48Price / Sales0.011.46394.10103.91Price / CashN/A6.5738.1834.62Price / Book-0.180.616.774.25Net Income-$20.63M-$153.72M$3.22B$248.23M7 Day PerformanceN/A1.00%3.25%3.29%1 Month PerformanceN/A-8.30%0.01%2.42%1 Year PerformanceN/A-27.53%18.00%5.54% BIOLASE Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BIOLBIOLASE0.7703 of 5 stars$0.01+2.5%$1.20+9,656.1%-91.7%$411,000.00$48.83M0.00160Analyst ForecastGap DownNVIVQInvivo TherapeuticsN/A$0.37flatN/AN/A$1.15MN/A0.006High Trading VolumeDYNTDynatronicsN/A$0.10+11.1%N/A-84.1%$1.06M$33.60M-0.12200Upcoming EarningsGap UpHigh Trading VolumeBJDXBluejay Diagnostics0.7354 of 5 stars$1.70+1.8%N/A-99.0%$942,000.00$250,000.000.009Positive NewsAFIBAcutus MedicalN/A$0.03-26.0%N/A-79.5%$899,000.00$7.16M0.00340Gap DownCUTRCutera1.3256 of 5 stars$0.04-63.9%$3.00+7,592.3%-98.4%$787,000.00$155.21M-0.01460Upcoming EarningsGap DownHigh Trading VolumeLGMKLogicMark0.6449 of 5 stars$0.01+48.3%N/A-99.9%$782,000.00$9.90M0.0020Short Interest ↑Gap UpHigh Trading VolumeSONXSonendoN/A$1.14flatN/A+1,118.6%$488,000.00$44.40M-0.02250GMVDFG Medical InnovationsN/A$0.00flatN/A-98.3%$52,000.00$4.42M0.0072SDCCQSmileDirectClubN/AN/AN/AN/A$40,000.00$470.74M0.002,700Gap DownVRAYQViewRayN/AN/AN/AN/A$18,000.00$102.21M0.00300 Related Companies and Tools Related Companies Invivo Therapeutics Alternatives Dynatronics Alternatives Bluejay Diagnostics Alternatives Acutus Medical Alternatives Cutera Alternatives LogicMark Alternatives Sonendo Alternatives G Medical Innovations Alternatives SmileDirectClub Alternatives ViewRay Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BIOL) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredChina’s next move could destroy U.S. techThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BIOLASE, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share BIOLASE With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BIOL Stock Free BIOL Stock Alerts